Abingworth Announces Leadership Transition
Abingworth, a prominent transatlantic investment firm in life sciences and a division of the global investment firm Carlyle, revealed various changes in leadership. Kurt von Emster, Managing Partner and Head of Abingworth Life Sciences, is moving to the role of Managing Partner at Abingworth.
Dr. Bali Muralidhar, Managing Partner, Chief Investment Officer, and Chief Operating Officer at Abingworth, has taken on the role of Head of Abingworth Life Sciences and CIO. Travis Wilson has come on board as Managing Director at both Abingworth and Carlyle, concentrating on clinical co-development and opportunities for biotech and pharma buyouts, thereby enhancing Carlyle’s life sciences division.
Kurt von Emster states, “Having led Abingworth for eleven years, which included the firm’s growth into clinical co-development and strategic partnership with Carlyle, Abingworth is now well-positioned to sustain its success as a leader in life sciences investment. I have collaborated closely with Dr. Bali Muralidhar for seven years, and he has shown the vision and leadership to carry on Abingworth’s 53 years of successful investing in life sciences."
Also Read: A Brief History of India's Transformation Under PM Narendra Modi
Kurt says, "I am confident that his leadership as Head of Abingworth Life Sciences will be advantageous for our investors, the Abingworth team, and the ongoing development of our top-tier transatlantic life sciences investment platform."
Also Read: 5 Latest CHRO Appointments in Global Corporations
“Kurt is a remarkable investor and has made substantial contributions to Abingworth since becoming part of the firm in 2015. His leadership has bolstered and expanded Abingworth. Dr. Bali Muralidhar expressed enthusiasm about further collaborating with Kurt to grow their unique life sciences investment venture.
“I am equally pleased that Travis Wilson is coming to Abingworth and Carlyle to concentrate on clinical co-development and biopharma buyout.” He offers extensive experience and a remarkable history as a life sciences investor and entrepreneur,” states Dr. Bali Muralidhar.
Also Read: How This Techie Turned Visa Struggles into Startup Success
Travis Wilson stated, “I am excited to collaborate with the Abingworth and Carlyle healthcare acquisition teams.” I think we are distinctly positioned as a source of capital solutions for biotech and pharmaceutical firms throughout the range of venture capital, clinical co-development, and buyout private equity.
Travis has more than 20 years of executive and investment experience in life sciences. Most recently, he served as a Growth Partner at Flagship Pioneering. Before that, Travis served as Managing Partner at Gurnet Point Capital. He was formerly the CEO of Stealth BioTherapeutics and part of the venture capital team at Morningside.